XBiotech Announces Enrollment Completion Of Phase II, Placebo Controlled, Multicenter Study For Natrunix In Pancreatic Cancer
Portfolio Pulse from Happy Mohamed
XBiotech Inc. has completed enrollment for the Phase II portion of its 1-BETTER study, a clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer. Natrunix is an antibody therapy that binds and neutralizes a substance that causes tumor growth and spread. The Phase II study enrolled 65 subjects to receive either Natrunix in combination with chemotherapy or a placebo. Key endpoints are safety and tolerability, progression-free survival, overall survival, and time-to-treatment-failure.
August 30, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
XBiotech's completion of enrollment for the Phase II study of Natrunix could potentially lead to positive outcomes for the company if the study results are favorable.
The completion of enrollment for the Phase II study of Natrunix is a significant milestone for XBiotech. If the study results are favorable, this could potentially lead to the approval of Natrunix as a treatment for pancreatic cancer, which would likely have a positive impact on XBiotech's stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100